Overview

Safety, Efficacy and Pharmacokinetics of BTA-C585 in a RSV Viral Challenge Study

Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the antiviral activity of oral BTA-C585 compared to placebo in healthy volunteers after intranasal challenge with RSV-A Memphis 37b virus.
Phase:
Phase 2
Details
Lead Sponsor:
Biota Pharma Europe Limited